UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Source: 
Endpoints
snippet: 

For a pharma company with about $5 billion in revenue, a couple of respectably sized blockbuster drugs on the market and some high-profile partners like Amgen, Belgium’s UCB has kept an unusually low profile on the pipeline side of things over the years.

Until now.